Salmefamol is a new sympathomimetic drug with predominantly P2 actions. In a double-blind trial in a group of twenty-four patients with airway obstruction, we have compared the effect of 100 tig of salmefamol given by metered aerosol with that of a placebo aerosol. In the same patients we have also compared the aerosols with subcutaneous adrenaline and subcutaneous atropine, the sequence of treatments being determined by a latin square design.
Introduction
Sympathomimetics are widely prescribed for the treatment of reversible airway obstruction. They can be carried in aerosol form ready for instant use, and they produce their greatest effect within a few minutes of inhalation. Lands et al. (1967) distinguished between the cardiac stimulant effect (pl) and the bronchodilator and vasodilator effects (02) of sympathomimetic drugs. This encouraged the search for sympathomimetics whose action on the airway would be greater than on the heart, achieving bronchodilation with minimal cardiac stimulation. A number of drugs producing selective P2 effect have since been introduced, including salbutamol (Cullum et al., 1969; Kennedy and Simpson,! 1969; ChooKang, Simpson and Grant, 1969) . Salmefamol, AH 3923, is a close chemical relative of salbutamol, AH 3365 ( Fig. 1) , with similar specificity in laboratory experiments (Hartley et al., 1968) . It bronchodilator effect of salbutamol when they are compared on a weight for weight basis, while the acute oral LD50 in mice and rats is over 1 g/kg (Brittain and Poynter, 1970 in FEV1 and FVC following treatment (Armitage, 1971a) . Procedure FEV1 and FVC were measured using an electronically timed spirometer (McKerrow, McDermott and Gilson, 1960) . All measurements were made by experienced laboratory technicians or by one of us (D.B.). The same person made all the measurements on a given patient in all but two instances. The highest value ofthree technically satisfactory attempts for each variable was used for the statistical analysis (Freedman and Prowse, 1966) .
The treatments consisted of (1) Salmefamol and the placebo were administered from identical aerosol canisters, each marked with a number code whose key was unknown to the investigators. The canister was shaken and discharged once into the air. One puff of aerosol was then administered by a technician whilst the patient slowly inhaled from functional residual capacity. The patient continued breathing in until total lung capacity was reached and then, after a short pause, exhaled normally. A second puff was administered in the same way about one minute later. This gave a total dose of 100 [Lg of salmefamol. The atropine group.bmj.com on July 2, 2017 -Published by http://pmj.bmj.com/ Downloaded from and the adrenaline were given by subcutaneous injection. The adrenaline injection was given slowly, taking up to 2 min. It was therefore not possible to use a double-blind procedure for these drugs. Each treatment was administered by 10 a.m. on consecutive mornings and was preceded by the initial measurements of the FEV1 and FVC. The measurements were repeated 20, 80, 120 and 240 min after the treatment. On the fifth day no treatment was given but a final measurement of FEV1 and FVC was made at 10 a.m.
All patients received each of the four treatments during the first 4 days of the trial. The order of treatments was determined by a latin square design suggested by Professor D. J. Finney. Each subgroup of four patients formed a 4 x 4 latin square and so all twenty-four of the possible sequences of the four treatments were used. With such a design, each patient acts as his own control, thus improving the precision with which effects of treatment are estimated. Any effect of the sequence of treatments can also be calculated and allowance made for this in the statistical analysis of comparisons (Armitage, 1971b) .
Results
The results below are presented in terms of the grouped values. Results of individual measurements on all patients can -be obtained from the authors. The value of such detailed information has been stressed by Oldham and Hughes (1972) .
The changes in FEV1 resulting from the different treatments, including the placebo, at the four different times after the dose are shown in Table 2 . The values are expressed as the mean increases in FEV1 over the pre-treatment values. The time course of the responses to the drugs is shown in Fig. 2 . Salmefamol can be seen to produce an effect significantly greater than that of the placebo at all times up to 240 min, the total duration of observation (P< 0 05). Atropine and adrenaline, in the doses used, caused greater responses than salmefamol at 20, 80 and 120 min. At 240 min, however, the response to salmefamol had persisted and the mean value for the increase in FEV1 was greater than that following atropine by more than twice the standard error of the difference of the means at this time (Table 2) . This difference is statistically significant at the 5 % level. The difference between salmefamol and adrenaline at 240 min is not statistically significant.
The pre-treatment values of FEV1 on the first day of the trial (Table 1 ) cover a wide range. Because of this it was thought possible that a different picture might emerge if changes in FEV1 were expressed as a percentage of the pre-treatment values rather than in absolute terms. However, analysis of these percentages revealed little alteration in the patterns of response.
The mean increase in FVC resulting from the different treatments is given in Table 3 . At all times salmefamol showed a larger increase than occurred with the placebo. Adrenaline and atropine gave higher values up to 120 min but the effect of these drugs on FVC had declined by 240 min. Although the effect of salmefamol on FVC at 240 min was greater than that of the other active drugs, the differences did not reach statistical significance. Table 3 shows No side effects were reported, or noticed after inhalation of either aerosol.
Discussion and conclusions
This study has demonstrated clearly that salmefamol produces bronchodilatation in man. Examination of the FEV1 curve (Fig. 2 ) reveals a consistent and prolonged effect after salmefamol lasting until the end of the study (4 hr). The statistical analysis has produced no evidence that salmefamol affected the next day's pre-treatment FEV1. These facts would suggest that it is effective for between 4 and 24 hr. The nature of this trial did not allow precise determination of the end-point. The clinical value of this new bronchodilator may lie in its long action, a property similar to that of salbutamol; it will therefore be important to compare its potency and duration of action directly with those of salbutamol over a longer time period. It will be of practical value to assess the effect of different doses of this new drug. In addition, it will be important to monitor the effects upon heart rate and blood pressure to see whether the specificity for P2 adrenergic receptors shown in animals is also applicable in man. 
